On Monday, MedLumics, a heart disease medical device research and development company from Spain, announced that it has completed a financing of 34.4 million euros (more than 200 million yuan). This round of financing is the largest single-round financing in the history of Spanish medical technology companies' financing, and it is also one of the largest rounds of financing in Europe's financing record this year.
The company that led the round of financing was Edmond de Rothschild Investment Partners (EdRIP), and other investors included new investors Seroba Life Sciences, Innogest Capital and the company's existing investors Ysios Capital Partners and Caixa Capital Risc.
It is reported that Innogest Capital partner Claudio Rumazza, EdRIP partner Olivier Litzka and Seroba Life Sciences James Green will join MedLumics' board of directors.
Founded in 2009, MedLumics specializes in the development of optically guided minimally invasive instruments. The company will use this round of financing to promote the clinical development of its AblaView series of catheters, which are mainly used to treat atrial fibrillation (AF) and other types of arrhythmias.
Atrial fibrillation (AF) is the most common arrhythmia disease that affects not only quality of life, but also disabling, fatal complications such as stroke or heart failure. According to 2010 statistics, approximately 33.5 million people worldwide have atrial fibrillation, and the number is still rising. The incidence of atrial fibrillation increases with age. With the increase of the elderly population over 65 years old, atrial fibrillation has become a disease that needs more attention.
(Tube radiofrequency ablation procedure: the red point in the figure is the place where the pulmonary veins are ablated around the two sides. The ablation point forms a circular ablation line, which isolates the abnormal electrical activity of the atrial fibrillation in the pulmonary vein from the left atrium, so that it can no longer be Excited atrial form atrial fibrillation. Image source: Good doctor online)
At present, the treatment of atrial fibrillation mainly includes three methods: drug treatment, electrical treatment and surgical treatment. Among them, catheter radiofrequency ablation is a radical treatment method. The therapy mainly sends the ablation device into the heart through the peripheral blood vessels, causing local myocardial necrosis by high-frequency current energy, and the pulmonary vein abnormality causing atrial fibrillation is blocked in the pulmonary vein. Make it impossible to conduct to the left atrium.
Radiofrequency catheter ablation is complicated and difficult to predict. About 60% of surgical patients will relapse after one year of follow-up. The cause of recurrence is often the reconnection of the patient's pulmonary veins. MedLumics' AblaView series of catheters are dedicated to changing this problem by providing the doctor with real-time information on the damage formation of the tissue surrounding the catheter during ablation.
Montreal Shantou Food Co., Ltd , https://www.montrealsnack.com